Epidermal growth factor receptor

Cat.No.	Product Name	Added

S1486	AEE788	Sep 2010
AEE788 is a novel multitargeted human epidermal receptor (HER) 1/2 and vascular endothelial growth factor receptor (VEGFR) 1/2 receptor family tyrosine kinases inhibitor with IC50 of 2, 6, 77, 59 nM for EGFR, ErbB2, KDR, and Flt-1.

S2728	AG-1478 (Tyrphostin AG-1478)	Jan 2012
AG-1478 (Tyrphostin AG-1478) is a highly potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with an IC50 of 3 nM.

S1143	AG-490	Jan 2010
AG 490 is a potent epidermal growth factor receptor kinase autophosphorylation inhibitor with an IC50 of 100 nM and 56.8 μM for EGFR and JAK, respectively.

S2733	AV-412	Dec 2011
AV-412 is a second-generation, orally bioavailable dual EGFR/HER2 tyrosine kinase inhibitor.

S2192	AZD8931	Jan 2011
AZD8931 is a novel potent reversible small molecule epidermal growth factor receptor, ERBB2 (HER2) and ERBB3 inhibitor with an IC50 of 4, 3, 4 nM, respectively.

S1011	BIBW2992 (Afatinib)	Apr 2009
BIBW2992 (Afatinib) is an irreversible EGFR/HER2 inhibitor with an IC50 of 0.5, 0.4, 10, 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2 in vitro, respectively.

S1056	BMS-599626 (AC480)	Apr 2009
BMS-599626 is a highly selective pan-HERKinase inhibitor with IC50 of 20 and 30 nM for the inhibition of HER1and HER2, respectively.

S2406	Chrysophanic acid (Chrysophanol)	Mar 2011
Chrysophanic acid (Chrysophanol) is a EGFR/mTOR pathway inhibitor.

S1194	CUDC-101	May 2010
CUDC-101 is a potent multitargeted HDAC, EGFR and HER2 inhibitor with IC50 of 4.4, 2.4, and 15.7 nM, respectively.

S1023	Erlotinib Hydrochloride	Apr 2009
Erlotinib Hydrochloride also known as Tarceva, CP-358774, OSI-774, NSC-718781 is a HCL salt with IC50 of 2 nM for HER1/EGFR TK.

S1025	Gefitinib(Iressa)	Apr 2009
Gefitinib also known as ZD-1839 & Iressa is a novel potent EGFR tyrosine kinase & Akt phosphorylations inhibitor with IC50 of 37, 26 and 57 nM.

S1028	Lapatinib (Tykerb)	Apr 2009
EGFR and HER2 autophosphorylation inhibitor, against purified EGFR and HER2 of 10.2 and 9.8 nM, respectively.

S2216	Mubritinib(TAK 165)	Mar 2011
Mubritinib(TAK 165) is a potent EGFR and p34cdc2 inhibitor with IC50 of 6 nM and 0.2 µM, respectively.

S2150	Neratinib (HKI-272)	Dec 2010
Neratinib (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor with IC50 of 59 nM and 92 nM for HER2 and EGFR, respectively.

S2205	OSI-420 (Desmethyl Erlotinib,CP-473420)	Mar 2011
OSI-420 (Desmethyl Erlotinib,CP-473420) is an active metabolite of erlotinib which is an orally active EGFR tyrosin kinase inhibitor with IC50 of 2 and 20 nM for the inhibition of human EGFR and EGFR autophosphorylation in tumor cells.

S1079	PD153035	Jul 2009
Inhibitor of EGFR, competitive with ATP. EGF Receptor: IC50 = 25 pM (Ki = 6 pM)

S1392	Pelitinib (EKB-569)	Jul 2010
Pelitinib (EKB-569) is a 3-cyanoquinoline pan-ErbB tyrosine kinase inhibitor with potential antineoplastic activity.

S2727	PF299804	Nov 2011
PF299804 is a potent, orally available, irreversible tyrosine kinase HER 1 (EGFR), HER2 and HER4 inhibitor with IC50 of 6, 45.7 and 73.7 nM for EGFR, ERBB2 and ERBB4, respectively.

S2622	PP121	Jun 2011
PP121 is a multitargeted dual receptor tyrosine kinases inhibitor with IC50 of 0.052, 1.4, 0.15, 1.1, 0.06, 0.01and 0.002 μM for p110α, p110β, p110δ, p110γ, DNA-PK, mTOR and PDGFR, respectively.

S1046	Vandetanib (Zactima)	Apr 2009
Vandetanib (Zactima) is a VEGFR and EGFR antagonist and a tyrosine kinase inhibitor with IC50 of 60, 90, 40 nM for HUVEC proliferation, PC-9 cells and tyrosine kinase activity, respectively.

S1170	WZ3146	Mar 2010
WZ3146 is an irreversiblely inhibitor against EGFR T790M.

S1173	WZ4002	Apr 2010
WZ4002 is an EGFR T790M inhibitor(IC50<20nM).

S1179	WZ8040	Apr 2010
WZ8040 is an irreversiblely EGFR T790M inhibitor (IC50<10nM).

S1083	XL647	Jul 2009
Inhibitor of the EGFR and ErbB2 with IC50 0.3 and 16 nM respectively.